Saturday 17 October 2026
Export WINT’s income statement to Excel — free account
Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow WINT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 3,208,423.25 | 405,000.41 | 276,750.28 | 275,400.28 | 180,000.19 | 62,140.56 | 6,750.01 | 603.45 | 14.68 |
Analyst estimates 2025–2027 Powerpack |
|||
| High | — | 11,933,045.00 | 4,991,360.50 | 784,350.81 | 722,250.75 | 600,750.63 | 284,845.78 | 73,125.07 | 17,149.52 | 737.44 | |||||
| People | |||||||||||||||
| People | Employees | — | 49 | 29 | 33 | 32 | 31 | 33 | 20 | 15 | 14 | ||||
| Revenue/emp, $m | — | 0.04 | 0.05 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | 2 | 1 | 2 | 0 | — | — | — | — | — | ||||
| Gross margin, % | — | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| EBT | — | (39) | (18) | (21) | (27) | (33) | (78) | (41) | (20) | (2) | |||||
| EBT margin, % | — | (1,933.89) | (1,242.15) | (1,148.38) | (13,876.26) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | (39) | (18) | (21) | (27) | (33) | (68) | (39) | (20) | (2) | |||||
| Depreciation | — | 2 | 1 | 1 | 0 | 0 | 45 | 20 | 3 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 4.91 | 1.44 | 0.40 | 990.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (94.93) | (3,256,621.00) | (1,044,169.00) | (113,320.70) | (93,525.19) | (122,751.80) | (55,962.23) | (4,712.23) | (104.35) | |||||
| Cash flow | — | (80.74) | (20.47) | (3.51) | (123,315.00) | (84,383.33) | (39,440.00) | (27,788.57) | (3,124.88) | (292.81) | |||||
| Capex | — | (0.61) | (0.02) | 0.00 | (955.00) | (970.00) | (465.00) | 281.43 | (3.49) | (0.23) | |||||
| Free cash flow | — | (81.35) | (20.50) | (3.51) | (124,270.00) | (85,353.33) | (39,905.00) | (27,507.14) | (3,128.37) | (293.04) | |||||
| Book value | — | (69.30) | (23.27) | 15.16 | 374,675.00 | 231,840.00 | 69,801.67 | 14,302.86 | 788.60 | 190.04 | |||||
| Shares, m | — | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | — | 698,506.32 | 475,684.11 | 1,696,184.62 | 228.59 | — | — | — | — | — | |||||
| P/B | — | 0.00 | 0.00 | 44,525.03 | 1.53 | — | — | — | — | — | |||||
| EV/Sales | — | 698,515.84 | 475,703.16 | 1,696,183.41 | 222.99 | — | — | — | — | — | |||||
| EV/FCF | — | (42,146.66) | (33,528.84) | (192,288.61) | (4.50) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (34) | (21) | (16) | (25) | (25) | (24) | (19) | (13) | (15) | ||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | (34) | (21) | (16) | (25) | (26) | (24) | (19) | (13) | (15) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | (6) | (10) | 5 | 16 | 12 | 19 | 5 | 1 | (3) | ||||
| Total debt | — | 25 | 15 | 23 | 20 | 18 | 15 | 15 | 15 | 1 | |||||
| Net debt | — | 19 | 13 | (2) | (3) | 1 | (7) | 9 | 11 | (1) | |||||
| Shareholders’ equity | — | (29) | (24) | 68 | 75 | 70 | 42 | 10 | 3 | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (146.05) | (380.44) | (56.63) | (23.05) | (28.09) | (72.08) | (69.55) | (57.68) | (18.20) | ||||
| ROIC | — | 0.00 | 0.00 | (15.35) | (21.57) | (26.92) | (138.69) | (135.31) | (89.99) | (178.02) | |||||
| ROE | — | 384.07 | 94.09 | (157.29) | (38.41) | (45.08) | (121.39) | (151.11) | (302.78) | (81.98) | |||||
Negative figures in brackets.
Fiscal years to Dec 2019 · latest quarter Dec 2019
Charts ten years each
Windtree Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| ELAB PMGC Holdings Inc. | $2.5M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| NTBLQ Notable Labs, Ltd. | $2.4M | — (loss-making) | — (loss-making) | −96.88% (below 0%: shrinking) | n/m | −26.63% (below 0%: shrinking) | 100.00% | (269,000.00%) | Compare |
| VBIO Valion Bio, Inc. | $2.4M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | — (loss-making) | — (loss-making) | +365,433.33% (above 0%: growing) | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | — (loss-making) | — | — | n/m | +53.15% (above 0%: growing) | 0.00% | — | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | |
| KAPA Kairos Pharma, Ltd. | $2.3M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $2.2M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| Median of peers | $2.4M | — | — | +147.70% | — | −8.28% | 0.00% | 0.00% |
Windtree Therapeutics, Inc. (WINT) Latest News
No news at this impact. Lower the threshold for more.